Oncolytics Biotech Inc. announced positive translational data from a Phase 1b/2 trial for its investigational immunotherapy, pelareorep, in patients with relapsed/refractory multiple myeloma. The findings demonstrate pelareorep's ability to engage the immune system, enhance antitumor immunity, and remodel the tumor microenvironment.
Key Details
- Trial Data: The data comes from a Phase 1b/2 study evaluating pelareorep in combination with standard therapies in heavily pretreated patients who had a median of four prior lines of therapy.
- Key Findings: Pelareorep treatment led to an increase in CD8 effector memory T cells, enhanced antigen-presenting activity, and direct biological effects on tumor cells, including increased apoptosis (programmed cell death).
- Upcoming Presentation: The full data will be presented as a poster at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition on December 12, 2026.